Strategic rationaleThe basket study marks a world-first initiative in neuropsychiatry and an important strategic milestone in the development of TRP-8803. The concurrent CTRA with Swinburne University also materially strengthens Entropy’s clinical development capability by expanding the operational infrastructure available for the basket study and future clinical programs. The basket study is designed to evaluate TRP-8803 across multiple neuropsychiatric indications using a common protocol and biomarker framework. The basket study will cost approximately A$3.2 million, which does not include the Company’s pending R&D Tax Incentive refund opportunities. The basket study may help identify biological and psychological characteristics associated with treatment response, supporting more personalised treatment approaches in future studies.